Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Burris

Physical Medicine & Rehabilitation Columbia, MO Medical Doctor

NPI 1093744690 CMS profile 186275

315 W Business Loop 70, Columbia, MO 65203

Open in the dashboard

General payments

$74,581

137 records reported · program years 2019–2025

Research payments

$1,878

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$616,882 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Joseph Burris of Columbia, MO is reported in the CMS Open Payments database as having received $74,581 across 137 general payments and $1,878 in research payments paid to them. Separately, studies naming them as principal investigator received $616,882 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,410 6
2024 General $18,103 34
2023 General $10,827 14
2022 General $10,552 19
2021 General $11,306 23
2020 General $4,301 14
2019 General $17,083 27
2019 Research $1,878 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Burris
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Joseph Burris were reported at $2,410. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Joseph Burris Physical Medicine & Rehabilitation median Middle half National median
2019 $17,083 $133 $45–$390 $163
2020 $4,301 $88 $29–$272 $114
2021 $11,306 $116 $33–$360 $132
2022 $10,552 $123 $40–$378 $149
2023 $10,827 $131 $43–$396 $160
2024 $18,103 $141 $45–$409 $164
2025 $2,410 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $35,166 41 payments
  2. Allergan Inc. $27,294 40 payments
  3. Merz North America, Inc. $7,336 20 payments
  4. Ipsen Biopharmaceuticals, Inc $1,850 7 payments
  5. Merz Pharmaceuticals, LLC $1,614 18 payments
  6. Pacira Pharmaceuticals Incorporated $1,117 9 payments
  7. Abbott Laboratories $135 1 payment
  8. E.R. Squibb & Sons, L.L.C. $69 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,975 34 payments
  2. Travel and Lodging $5,949 26 payments
  3. Honoraria $5,450 2 payments
  4. Food and Beverage $4,157 73 payments
  5. Consulting Fee $2,050 2 payments
Products named General payments · program years 2019–2025
  1. BOTOX Neuroscience $51,213 59 payments
  2. BOTOX Neuroscience $9,950 10 payments
  3. Xeomin musculoskeletal $8,153 35 payments
  4. DYSPORT $1,850 7 payments
  5. Zilretta $1,117 9 payments
  6. BOTOX Botox Therapeutic $954 4 payments
  7. BOTOX Hyperhydrosis $344 8 payments
  8. Xeomin musculoskeletal $262 2 payments
  9. PROCLAIM $135 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Merz North America, Inc. $1,878 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

304

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$7,633

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

13.5%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Baclofen Generic 106 $2,857
Gabapentin Generic 95 $1,828
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $1,024
Morphine Sulfate Generic 13 $887
Morphine Sulfate Er Morphine Sulfate Brand 13 $259
Sertraline Hcl Generic 12 $235
Memantine Hcl Generic 12 $216
Tramadol Hcl Generic 13 $197
Amantadine Amantadine Hcl Brand 13 $112
Alprazolam Generic 12 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$43,274

Medicare's payments for the services billed

Medicare patients

232

Average age 71

Services billed

727

104 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 50%
Depression 46%
Chronic kidney disease 42%
Ischemic heart disease 38%
Heart failure 37%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $16,172
$16,172 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $1,117
$1,117 — —
Xeomin
  • Merz Pharmaceuticals, LLC $262
$262 — —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record